ArticleProceedings of the National Academy of Sciences of the United States of America1996
Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Impact of the optical depth of field on cytogenetic image quality.Journal of biomedical optics · 2012Article
- Inactivation of SLIT2-ROBO1/2 pathway in premalignant lesions of uterine cervix: clinical and prognostic significances.PloS one · 2012Article
- Deciphering squamous cell carcinoma using multidimensional genomic approaches.Journal of skin cancer · 2011Article
- Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.Genes, chromosomes & cancer · 2009Article
- Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene.Human genetics · 2007Article
- Deletion in chromosome 11 and Bcl-1/Cyclin D1 alterations are independently associated with the development of uterine cervical carcinoma.Journal of cancer research and clinical oncology · 2005Article
- Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients.Molecular pathology : MP · 2003Article
- End-sequence profiling: sequence-based analysis of aberrant genomes.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability.The Journal of molecular diagnostics : JMD · 2002Article
- Multiplexed analysis of post-PCR fluorescence-labeled microsatellite alleles and statistical evaluation of their imbalance in brain tumors.Japanese journal of cancer research : Gann · 2002Article
- The molecular genetics of cervical carcinoma.British journal of cancer · 1999Review
- Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas.The American journal of pathology · 1999Article
- Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR.Genome research · 1999Article
- Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations.British journal of cancer · 1999Article
- Localization of a novel tumor suppressor gene associated with human oral cancer on chromosome 4q25.Oncogene · 1999Article
- Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity.The American journal of pathology · 1998Article
- Molecular events in uterine cervical cancer.Sexually transmitted infections · 1998Review
- Functional evidence for a nasopharyngeal carcinoma tumor suppressor gene that maps at chromosome 3p21.3.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- A mortality gene(s) for the human adenocarcinoma line HeLa maps to a 130-kb region of human chromosome 4q22-q23.Neoplasia (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detection of loss of heterozygosity (LOH) by comparison of normal and tumor genotypes using PCR-based microsatellite loci provides considerable advantages over traditional Southern blotting-based approaches. However, current methodologies are limited by several factors, including the numbers of loci that can be evaluated for LOH in a single experiment, the discrimination of true alleles versus "stutter bands," and the use of radionucleotides in detecting PCR products. Here we describe methods for high throughput simultaneous assessment of LOH at multiple loci in human tumors; these methods rely on the detection of amplified microsatellite loci by fluorescence-based DNA sequencing technology. Data generated by this approach are processed by several computer software programs that enable the automated linear quantitation and calculation of allelic ratios, allowing rapid ascertainment of LOH. As a test of this approach, genotypes at a series of loci on chromosome 4 were determined for 58 carcinomas of the uterine cervix. The results underscore the efficacy, sensitivity, and remarkable reproducibility of this approach to LOH detection and provide subchromosomal localization of two regions of chromosome 4 commonly altered in cervical tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.